Circadian Technologies (ASX:CIR) has posted a AUD$5.8 million profit for the 2003-04 financial year, and the prospects of an even better year next year thanks to the recent acquisition of its investee company Axon Instruments by US firm Molecular Devices on July 1. [ + ]

Production facilities at Chemeq (ASX:CMQ) have finally come to life, with the company announcing that it has manufactured enough of the active pharmaceutical ingredient of its novel antimicrobial to verify the production process. [ + ]

Melbourne-based agbiotech company Hexima will make a small piece of biotech history in October by becoming the first homegrown Victorian company to trial a genetically modified field crop. [ + ]

Sydney pharmaceutical company Pharmaxis (ASX:PXS) has completed enrolling 600 asthma patients for a phase III trial of its patented asthma prognostic, Aridol. [ + ]

South Australian genomics company Bionomics (ASX:BNO) has shaken hands with Louisiana State University’s Health Sciences Centre (LSUHSC) on a landmark collaboration to explore the efficacy of the company’s gene-silencing constructs as a gene therapy for solid tumours. [ + ]

Meditech (ASX: MTR) is looking for a new CEO as CEO Chris Carter steps down, three months after a shareholder stoush forced his resignation from the company. [ + ]

Brisbane-based Benitec (ASX: BLT) has announced a loss of AUD$1.9 million for the quarter, and confirmed that it has just $4.65 million remaining in cash. [ + ]

Prima Biomed (ASX: PRR) subsidiary CancerVac began a Phase IIa clinical trial today to evaluate its immunotherapy in patients with ovarian cancer. [ + ]

New Sydney University spinoff Elastagen is courting potential investors and commercial collaborators to develop organ-and-tissue-engineering applications for its super-stretchy protein, tropoelastin. [ + ]

Peplin Biotech (ASX:PEP) has claimed its lead molecule PEP005 has shown highly selective activity against acute myelogenous leukaemia (AML) in pre-clinical studies. [ + ]

Several Australian biotechs, including Novogen, Proteome Systems, Starpharma and Ventracor, were winners in the second round of Australian Research Council (ARC) linkage grants, announced earlier this month. [ + ]

Revenir (ASX: REV) has achieved the first step in its proposed merger with British biotech company Bone with the raising of more than AUD$1.5 million in a share placement. [ + ]

New Zealand company Genesis R&D (NZX/ASX: GEN) has laid off more than half of the staff from its subsidiary AgriGenesis, due to a lack of success in raising capital for the spin-out company. [ + ]

Sydney-based devices company Polartechnics (ASX:PLT) today announced its product-sales revenue had increased four-fold to AUD$2.14 million for the financial year ended June 30 2004. [ + ]

Scientists and fishers will use deep ocean acoustic remote sensing techniques developed by CSIRO to help give long-term sustainability to the largest fishery in Australia's south-east.